BACKGROUND: Diabetes management requires complex and interdisciplinary cooperation of health care professionals (HCPs). To support this complex process, IT-support is recommended by clinical guidelines. The aim of this article is to report on results from a clinical feasibility study testing the prototype of a mobile, tablet-based client-server system for computerized decision and workflow support (GlucoTab®) and to discuss its impact on hypoglycemia prevention. METHODS: The system was tested in a monocentric, open, noncontrolled intervention study in 30 patients with type 2 diabetes mellitus (T2DM). The system supports HCPs in performing a basal-bolus insulin therapy. Diabetes therapy, adverse events, software errors and user feedback were documented. Safety, efficacy and user acceptance of the system were investigated. RESULTS: Only 1.3% of blood glucose (BG) measurements were <70 mg/dl and only 2.6% were >300 mg/dl. The availability of the system (97.3%) and the rate of treatment activities documented with the system (>93.5%) were high. Only few suggestions from the system were overruled by the users (>95.7% adherence). Evaluation of the 3 anonymous questionnaires showed that confidence in the system increased over time. The majority of users believed that treatment errors could be prevented by using this system. CONCLUSIONS: Data from our feasibility study show a significant reduction of hypoglycemia by implementing a computerized system for workflow and decision support for diabetes management, compared to a paper-based process. The system was well accepted by HCPs, which is shown in the user acceptance analysis and that users adhered to the insulin dose suggestions made by the system.
BACKGROUND:Diabetes management requires complex and interdisciplinary cooperation of health care professionals (HCPs). To support this complex process, IT-support is recommended by clinical guidelines. The aim of this article is to report on results from a clinical feasibility study testing the prototype of a mobile, tablet-based client-server system for computerized decision and workflow support (GlucoTab®) and to discuss its impact on hypoglycemia prevention. METHODS: The system was tested in a monocentric, open, noncontrolled intervention study in 30 patients with type 2 diabetes mellitus (T2DM). The system supports HCPs in performing a basal-bolus insulin therapy. Diabetes therapy, adverse events, software errors and user feedback were documented. Safety, efficacy and user acceptance of the system were investigated. RESULTS: Only 1.3% of blood glucose (BG) measurements were <70 mg/dl and only 2.6% were >300 mg/dl. The availability of the system (97.3%) and the rate of treatment activities documented with the system (>93.5%) were high. Only few suggestions from the system were overruled by the users (>95.7% adherence). Evaluation of the 3 anonymous questionnaires showed that confidence in the system increased over time. The majority of users believed that treatment errors could be prevented by using this system. CONCLUSIONS: Data from our feasibility study show a significant reduction of hypoglycemia by implementing a computerized system for workflow and decision support for diabetes management, compared to a paper-based process. The system was well accepted by HCPs, which is shown in the user acceptance analysis and that users adhered to the insulin dose suggestions made by the system.
Entities:
Keywords:
basal-bolus insulin therapy; best practice; computerized decision support; diabetes mellitus type 2; hypoglycemia; medication management system
Authors: Mohammad Hassan Murad; John A Coburn; Fernando Coto-Yglesias; Svitlana Dzyubak; Ahmad Hazem; Melanie A Lane; Larry J Prokop; Victor M Montori Journal: J Clin Endocrinol Metab Date: 2011-11-16 Impact factor: 5.958
Authors: Annette Moxey; Jane Robertson; David Newby; Isla Hains; Margaret Williamson; Sallie-Anne Pearson Journal: J Am Med Inform Assoc Date: 2010 Jan-Feb Impact factor: 4.497
Authors: Bernhard Höll; Stephan Spat; Johannes Plank; Lukas Schaupp; Katharina Neubauer; Peter Beck; Franco Chiarugi; Vasilis Kontogiannis; Thomas R Pieber; Andreas Holzinger Journal: Stud Health Technol Inform Date: 2011
Authors: Boris Draznin; Janice Gilden; Sherita H Golden; Silvio E Inzucchi; David Baldwin; Bruce W Bode; Jeffrey B Boord; Susan S Braithwaite; Enrico Cagliero; Kathleen M Dungan; Mercedes Falciglia; M Kathleen Figaro; Irl B Hirsch; David Klonoff; Mary T Korytkowski; Mikhail Kosiborod; Lillian F Lien; Michelle F Magee; Umesh Masharani; Gregory Maynard; Marie E McDonnell; Eti S Moghissi; Neda Rasouli; Daniel J Rubin; Robert J Rushakoff; Archana R Sadhu; Stanley Schwartz; Jane Jeffrie Seley; Guillermo E Umpierrez; Robert A Vigersky; Cecilia C Low; Deborah J Wexler Journal: Diabetes Care Date: 2013-07 Impact factor: 19.112
Authors: Guillermo E Umpierrez; Dawn Smiley; Kathie Hermayer; Amna Khan; Darin E Olson; Christopher Newton; Sol Jacobs; Monica Rizzo; Limin Peng; David Reyes; Ingrid Pinzon; Maria Eugenia Fereira; Vicky Hunt; Ashwini Gore; Marcos T Toyoshima; Vivian A Fonseca Journal: Diabetes Care Date: 2013-02-22 Impact factor: 19.112
Authors: Guillermo E Umpierrez; Dawn Smiley; Sol Jacobs; Limin Peng; Angel Temponi; Patrick Mulligan; Denise Umpierrez; Christopher Newton; Darin Olson; Monica Rizzo Journal: Diabetes Care Date: 2011-01-12 Impact factor: 19.112
Authors: Guillermo E Umpierrez; Roma Gianchandani; Dawn Smiley; Sol Jacobs; David H Wesorick; Christopher Newton; Farnoosh Farrokhi; Limin Peng; David Reyes; Sangeeta Lathkar-Pradhan; Francisco Pasquel Journal: Diabetes Care Date: 2013-07-22 Impact factor: 19.112
Authors: Julia Kopanz; Katharina M Lichtenegger; Constanze Koenig; Angela Libiseller; Julia K Mader; Klaus Donsa; Thomas Truskaller; Norbert Bauer; Brigitte Hahn; Gerald Sendlhofer; Peter Beck; Bernhard Höll; Frank Sinner; Franz Feichtner; Thomas R Pieber Journal: J Diabetes Sci Technol Date: 2020-09-16
Authors: Felix Aberer; Katharina M Lichtenegger; Edin Smajic; Klaus Donsa; Oliver Malle; Judith Samonigg; Bernhard Höll; Peter Beck; Thomas R Pieber; Johannes Plank; Julia K Mader Journal: Diabetes Obes Metab Date: 2018-11-11 Impact factor: 6.577